FDA Endorses Human-Centric Drug Testing

The U.S. Food and Drug Administration has released draft guidance endorsing New Approach Methodologies (NAMs) as alternatives to traditional animal testing in drug development.

The move prioritizes human-centric models such as organ-on-chips, 3D organoids, and AI-powered in silico simulations, which better predict human responses than animal trials.

Dr. Marty Makary, FDA Commissioner, stated that technology now allows a departure from animal testing, which historically failed to reliably forecast safety and efficacy in humans.

The FDA established four validation pillars: context of use, human biological relevance, technical characterisation, and fit-for-purpose.

Pharma companies are encouraged to engage with FDA medical teams early to align novel methods with disease-specific regulatory needs.